HIV-1 structural gene expression requires binding of the Rev trans-activator to its RNA target sequence - PubMed

HIV-1 structural gene expression requires binding of the Rev trans-activator to its RNA target sequence

M H Malim et al. Cell. 1990.

Abstract

Expression of human immunodeficiency virus type 1 structural proteins requires both the viral Rev trans-activator and its cis-acting RNA target sequence, the Rev response element (RRE). The RRE has been mapped to a conserved region of the HIV-1 env gene and is predicted to form a complex, highly stable RNA stem-loop structure. Site-directed mutagenesis was used to define a small subdomain of the RRE, termed stem-loop II, that is essential for biological activity. Gel retardation assays demonstrated that the Rev trans-activator is a sequence-specific RNA binding protein. The RRE stem-loop II subdomain was found to be both necessary and sufficient for the binding of Rev by the RRE. We propose that the HIV-1 Rev trans-activator belongs to a new class of sequence-specific RNA binding proteins characterized by the presence of an arginine-rich binding motif.

Similar articles

• Function of the human immunodeficiency virus types 1 and 2 Rev proteins is dependent on their ability to interact with a structured region present in env gene mRNA.

  Dillon PJ, Nelbock P, Perkins A, Rosen CA. Dillon PJ, et al. J Virol. 1990 Sep;64(9):4428-37. doi: 10.1128/JVI.64.9.4428-4437.1990. J Virol. 1990. PMID: 2200888 Free PMC article.

• HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency.

  Malim MH, Cullen BR. Malim MH, et al. Cell. 1991 Apr 19;65(2):241-8. doi: 10.1016/0092-8674(91)90158-u. Cell. 1991. PMID: 2015625

• Inhibition of HIV-1 replication by targeting the Rev protein.

  Nakaya T, Iwai S, Fujinaga K, Otsuka E, Ikuta K. Nakaya T, et al. Leukemia. 1997 Apr;11 Suppl 3:134-7. Leukemia. 1997. PMID: 9209321 Review.

• RNA-sequence-mediated gene regulation in HIV-1.

  Cullen BR. Cullen BR. Infect Agents Dis. 1994 Apr-Jun;3(2-3):68-76. Infect Agents Dis. 1994. PMID: 7812657 Review.

Cited by

• HIV-1 and M-PMV RNA Nuclear Export Elements Program Viral Genomes for Distinct Cytoplasmic Trafficking Behaviors.

  Pocock GM, Becker JT, Swanson CM, Ahlquist P, Sherer NM. Pocock GM, et al. PLoS Pathog. 2016 Apr 12;12(4):e1005565. doi: 10.1371/journal.ppat.1005565. eCollection 2016 Apr. PLoS Pathog. 2016. PMID: 27070420 Free PMC article.

• Novel human endogenous sequences related to human immunodeficiency virus type 1.

  Horwitz MS, Boyce-Jacino MT, Faras AJ. Horwitz MS, et al. J Virol. 1992 Apr;66(4):2170-9. doi: 10.1128/JVI.66.4.2170-2179.1992. J Virol. 1992. PMID: 1548756 Free PMC article.

• Mutational analysis of the human immunodeficiency virus type 1 Rev transactivator: essential residues near the amino terminus.

  Hope TJ, McDonald D, Huang XJ, Low J, Parslow TG. Hope TJ, et al. J Virol. 1990 Nov;64(11):5360-6. doi: 10.1128/JVI.64.11.5360-5366.1990. J Virol. 1990. PMID: 2120472 Free PMC article.

• Function of the human immunodeficiency virus types 1 and 2 Rev proteins is dependent on their ability to interact with a structured region present in env gene mRNA.

  Dillon PJ, Nelbock P, Perkins A, Rosen CA. Dillon PJ, et al. J Virol. 1990 Sep;64(9):4428-37. doi: 10.1128/JVI.64.9.4428-4437.1990. J Virol. 1990. PMID: 2200888 Free PMC article.

• Extensive sequence-specific information throughout the CAR/RRE, the target sequence of the human immunodeficiency virus type 1 Rev protein.

  Dayton ET, Konings DA, Powell DM, Shapiro BA, Butini L, Maizel JV, Dayton AI. Dayton ET, et al. J Virol. 1992 Feb;66(2):1139-51. doi: 10.1128/JVI.66.2.1139-1151.1992. J Virol. 1992. PMID: 1731093 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database